1370409-28-1 Usage
Uses
Used in Pharmaceutical Industry:
Saxagliptin hydrochloride Monohydrate is used as an antidiabetic medication for managing type 2 diabetes. It functions by inhibiting the DPP-4 enzyme, which in turn promotes increased insulin secretion and decreased blood glucose levels, thereby improving overall blood sugar control.
Used in Diabetes Management:
Saxagliptin hydrochloride Monohydrate is used as a therapeutic agent for adults with type 2 diabetes to help regulate blood sugar levels. It is particularly beneficial when used in conjunction with a healthy diet and regular physical activity, which are essential components of diabetes management.
Common side effects associated with Saxagliptin hydrochloride Monohydrate may include headache, urinary tract infections, and upper respiratory infections. However, it is crucial to note that more serious side effects such as pancreatitis and allergic reactions can occur, necessitating cautious use and supervision by a healthcare professional.
Check Digit Verification of cas no
The CAS Registry Mumber 1370409-28-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,0,4,0 and 9 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1370409-28:
(9*1)+(8*3)+(7*7)+(6*0)+(5*4)+(4*0)+(3*9)+(2*2)+(1*8)=141
141 % 10 = 1
So 1370409-28-1 is a valid CAS Registry Number.
1370409-28-1Relevant articles and documents
CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME
-
Page/Page column 32, (2008/12/08)
Physical crystal structures of a compound of the formula (I): are provided including the free base monohydrate thereof (form H-1) and the hydrochloric acid salt thereof, including hydrochloric acid salt containing 0.75 equivalent of H2O (form H0.75-3) and hydrochloric acid salt containing 2 equivalents of H2O (form H2-1), and hydrochloric acid salt Pattern P-5, preferably in substantially pure form, and other forms as described herein, pharmaceutical compositions containing structures of compound I or IA, processes for preparing same, intermediates used in preparing same, and methods of treating diseases such as diabetes using such structures.
